A process for treating adult respiratory distress syndrome by the systemic administration of ibuprofen (p-isobutylhydratropic acid) or a salt or ester thereof. Dosage forms are also disclosed.
A stabilized liquid ibuprofen syrup suitable for oral administration comprising: from 50 to 400 mg of ibuprofen per 5 ml of syrup; said ibuprofen suspended in an aqueous liquid having more than 50% by weight of a pharmaceutically acceptable polyhydric alcohol bodying agent; a sweetening agent; and a pH of higher than 7.0 and below 7.7.
A novel method for preventing, stabilizing or causing regression of vascular leak syndrome is disclosed. The method comprises administering to a patient in need thereof a compound selected from the group consisting of a corticosteroid, a non-steroidal anti-inflammatory agent, 15-deoxyspergualin and related compounds, and phospholipase A.sub.2 inhibitors.
This invention relates to methods for treating Adult Respiratory Distress Syndrome (ARDS) which involves the administration of 2,3-alkylcarbonyloxybenzoic acid and salts thereof wherein the alkyl group has 2-18 carbon atoms.
A clear, stable, and palatable liquid ibuprofen composition has ibuprofen, or a pharmaceutically acceptable salt or ester of ibuprofen, in an aqueous medium containing a methylcellulose composition. A process of making such an ibuprofen composition is significantly simpler and less expensive to carry out than prior processes of making liquid ibuprofen compositions. The liquid ibuprofen composition may also contain pharmaceutically acceptable alcohol, dispersing and suspending agents, viscosity increasing agents, flavorings, and preservatives.
A novel water soluble alkali metal salt of ibuprofen is prepared by reacting ibuprofen and an alkali metal bicarbonate in a aqueous medium. The salt is useful in treating pain, inflammation, and fever in mammals. It permits the preparation of a number of novel formulations which result in pharmaceutically and commercially acceptable dosage forms.
